Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology
Clinical Trials: Mesothelioma
A listing of clinical trials currently looking for volunteers to enroll in Mesothelioma studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : University of Alabama at Birmingham
ChemoFx® PRO - A Post-Market Data Collection Study
Birmingham : University of Alabama at Birmingham
Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)
Mobile : USA Mitchell Cancer Institute
ChemoFx® PRO - A Post-Market Data Collection Study
Arizona
Scottsdale : Site Reference ID/Investigator# 64046
Study of ABT-700 in Subjects With Advanced Solid Tumors
California
Duarte : City of Hope-Comprehensive Cancer Cente
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
Los Gatos : Bay Area Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
San Francisco : University of California San Francisco
ChemoFx® PRO - A Post-Market Data Collection Study
San Jose : San Jose Women's Medical Group
ChemoFx® PRO - A Post-Market Data Collection Study
Sherman Oaks : Women's Cancer Center Sherman Oaks
ChemoFx® PRO - A Post-Market Data Collection Study
View More »
Torrance : GOA Torrance Memorial
ChemoFx® PRO - A Post-Market Data Collection Study
Florida
Boca Raton : South Florida Center for Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Clearwater : West Coast Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Delray Beach : Comprehensive Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Fort Lauderdale : Caruso and Gates MDs PA
ChemoFx® PRO - A Post-Market Data Collection Study
Fort Myers : Florida Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
View More »
Pembroke Pines : Gynecologic Oncology Associates
ChemoFx® PRO - A Post-Market Data Collection Study
Sarasota : Sarasota Memorial Hospital
ChemoFx® PRO - A Post-Market Data Collection Study
South Miami : South Miami Gynecologic Oncology Group
ChemoFx® PRO - A Post-Market Data Collection Study
West Palm Beach : Palm Beach Cancer Institute
ChemoFx® PRO - A Post-Market Data Collection Study
Georgia
Riverdale : Southeastern Gynecologic Oncology, LLC
ChemoFx® PRO - A Post-Market Data Collection Study
Savannah : Memorial Health University Medical Center
ChemoFx® PRO - A Post-Market Data Collection Study
Hawaii
Honolulu : The Queens' Medical Center
ChemoFx® PRO - A Post-Market Data Collection Study
Illinois
Chicago : University of Chicago
An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma
Chicago : Rush University
ChemoFx® PRO - A Post-Market Data Collection Study
Evanston : NorthShore Medical Group
ChemoFx® PRO - A Post-Market Data Collection Study
Indiana
Indianapolis : Indiana University
ChemoFx® PRO - A Post-Market Data Collection Study
Louisiana
Covington : Women's Cancer Center
ChemoFx® PRO - A Post-Market Data Collection Study
Shreveport : CHRISTUS Schumpert Health System
ChemoFx® PRO - A Post-Market Data Collection Study
Maryland
Baltimore : Sinai Hospital
ChemoFx® PRO - A Post-Market Data Collection Study
Baltimore : Johns Hopkins
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
Bethesda : National Cacner Institue
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
Silver Springs : Women's Health Specialists
ChemoFx® PRO - A Post-Market Data Collection Study
Massachusetts
Worcester : UMass Memorial Hospital
ChemoFx® PRO - A Post-Market Data Collection Study
Michigan
Detroit : Karmanos Cancer Institute
ChemoFx® PRO - A Post-Market Data Collection Study
Detroit : Henry Ford Health System
ChemoFx® PRO - A Post-Market Data Collection Study
Detroit : Site Reference ID/Investigator# 57555
Study of ABT-700 in Subjects With Advanced Solid Tumors
Grand Rapids : Gynecologic Oncology of West Michigan
ChemoFx® PRO - A Post-Market Data Collection Study
Mississippi
Jackson : Mississippi Oncology Associates
ChemoFx® PRO - A Post-Market Data Collection Study
New Jersey
Basking Ridge : Memorial Sloan-Kettering at Basking Ridge
Study Using Chemotherapy +/- Pleurectomy/Decortication Followed By Intensity Modulated Radiation Therapy
Teaneck : Gara M Sommers MD
ChemoFx® PRO - A Post-Market Data Collection Study
Voorhees : Cooper Health System
ChemoFx® PRO - A Post-Market Data Collection Study
New York
Albany : Women's Cancer Care Associates
ChemoFx® PRO - A Post-Market Data Collection Study
Atlantic Beach : St. John's Episcopal Hospital
ChemoFx® PRO - A Post-Market Data Collection Study
Bronx : Montefiore Medical Center
ChemoFx® PRO - A Post-Market Data Collection Study
Buffalo : Roswell Park Cancer Institute
ChemoFx® PRO - A Post-Market Data Collection Study
Commack : Memorial Sloan-Kettering Cancer Center @ Suffolk
Study Using Chemotherapy +/- Pleurectomy/Decortication Followed By Intensity Modulated Radiation Therapy
View More »
Manhassett : North Shore LIJ Health System
ChemoFx® PRO - A Post-Market Data Collection Study
New York : New York University Cancer Center
An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma
New York : Columbia University
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
New York : Columbia University Medical Center
Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide
New York : Memorial Sloan-Kettering Cancer Center
Study Using Chemotherapy +/- Pleurectomy/Decortication Followed By Intensity Modulated Radiation Therapy
Rockville Centre : Memorial Sloan-Kettering at Mercy Medical Center
Study Using Chemotherapy +/- Pleurectomy/Decortication Followed By Intensity Modulated Radiation Therapy
Sleepy Hollow : Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
Study Using Chemotherapy +/- Pleurectomy/Decortication Followed By Intensity Modulated Radiation Therapy
North Carolina
Asheville : Hope: A Women's Cancer Center
ChemoFx® PRO - A Post-Market Data Collection Study
Charlotte : Blumenthal Cancer Center
ChemoFx® PRO - A Post-Market Data Collection Study
Charlotte : Presbyterian Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Durham : Duke University Medical Center
ChemoFx® PRO - A Post-Market Data Collection Study
Durham : Site Reference ID/Investigator# 66111
Study of ABT-700 in Subjects With Advanced Solid Tumors
View More »
Wilmington : North Hanover Regional Medical Center
ChemoFx® PRO - A Post-Market Data Collection Study
Ohio
Cincinnati : University of Cincinnati
ChemoFx® PRO - A Post-Market Data Collection Study
Columbus : OSU Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Oklahoma
Oklahoma City : Oklahoma Gynecologic Oncology Group
ChemoFx® PRO - A Post-Market Data Collection Study
Oregon
Portland : Oregon Health & Science University
ChemoFx® PRO - A Post-Market Data Collection Study
Pennsylvania
Pittsburgh : Pittsburgh Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
South Dakota
Sioux Falls : Sandford USD Health System
ChemoFx® PRO - A Post-Market Data Collection Study
Tennessee
Chattanooga : Chattanooga Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Chattanooga : Chattanooga's Program in Women's Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Knoxville : Thomas W. McDonald MD
ChemoFx® PRO - A Post-Market Data Collection Study
Texas
Houston : S. R. Burzynski Clinic
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Mesothelioma
View More »
Dallas : North Texas Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Dallas : UTsouthwestern medical center
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
Ft. Sam Houston : Brooke Army Medical Center
ChemoFx® PRO - A Post-Market Data Collection Study
San Antonio : South Texas Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Virginia
Annandale : North Virigina Pelvic Surgery Associates
ChemoFx® PRO - A Post-Market Data Collection Study
Roanoke : Carilion Clinic Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
West Virginia
Morgantown : Mohammed Ashraf MD
ChemoFx® PRO - A Post-Market Data Collection Study
Wisconsin
West Allis : Aurora West Allis Medical Center
ChemoFx® PRO - A Post-Market Data Collection Study
Belgium
Ghent : University Hospital Ghent
A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.
Mechelen : AZ St. Maarten
A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.
Canada
Edmonton : UAB - Alberta Cancer Board - Cross Cancer Institute
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
Toronto : University Health Network
Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma
Egypt
Cairo : National Cancer Institute
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
Ireland
Dublin : St James's Hospital
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
Italy
Alessandria : Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma
Aviano : Centro di Riferimento Oncologico
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
Como : Ospedale Valduce
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
Genoa : Istituto Nazionale per la Ricerca sul Cancro
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
Genova : Asl 3 genovese, Ospedale Villa Scassi
Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma
View More »
Milan : Fondazione San Raffaele del Monte Tabor
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
Monferrato : Ospedale Santo Spirito
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
Monza : Azienda Ospedaliera San Gerardo
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
Orbassano : Azienda Ospedaliera Universitaria San Luigi Gonzaga
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
Padova : Istituto Oncologico Veneto
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
Parma : Azienda Ospedaliero Universitaria di Parma
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
Pavia : IRCCS Policlinico S. Matteo
Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma
Rho : A.O. Salvini Garbagnate, Ospedale di Rho
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
Rozzano : Istituto Clinico Humanitas
Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma
Treviso : Ospedale Ca' Foncello
Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma
Netherlands
Poland
Gdansk : Medical University of Gdansk
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
Warsaw : Maria Sklodowska Memorial Cancer Center and Institute of Oncology
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
United Kingdom
London : The Royal Marsden Hospital
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
London : Guy's Hospital
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
Maidstone : Kent Oncology Centre Maidstone Hospital
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
Middlesex : Mount Vernon Cancer Centre
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
Sutton : The Royal Marsden Hospital
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
